Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-03-04

FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)

View source ↗

Summary

The FDA approved a supplemental application for Aimovig (erenumab-aooe) by Amgen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AIMOVIG (ERENUMAB-AOOE)

Snippet

SUPPL AP for AIMOVIG (ERENUMAB-AOOE)